BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
96.96
+4.90 (5.32%)
At close: Oct 9, 2026, 4:00 PM EDT
96.81
-0.15 (-0.15%)
After-hours: Oct 9, 2026, 7:33 PM EDT
BioNTech SE Revenue
BioNTech SE had revenue of 145.80M EUR in the quarter ending June 30, 2026, a decrease of -56.99%. This brings the company's revenue in the last twelve months to 2.78B, down -3.41% year-over-year. In the year 2025, BioNTech SE had annual revenue of 3.05B with 5.63% growth. That makes BioNTech SE the 3,764th largest company in the world by revenue and 1,040th in the United States.
Revenue (ttm)
2.78B EUR
Revenue Growth
-3.41%
P/S Ratio
8.05
Revenue / Employee
356,129 EUR
Employees
7,807
Market Cap
24.36B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.05B | 162.80M | 5.63% |
| Dec 31, 2024 | 2.89B | -1.03B | -26.31% |
| Dec 31, 2023 | 3.92B | -13.39B | -77.33% |
| Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
| Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
| Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
| Dec 31, 2019 | 108.60M | -18.98M | -14.87% |
| Dec 31, 2018 | 127.58M | 65.98M | 107.11% |
| Dec 31, 2017 | 61.60M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 6.13B |
| Incyte | 5.82B |
| Alnylam Pharmaceuticals | 4.80B |
| Jazz Pharmaceuticals | 4.60B |
| Genmab | 4.13B |
| Royalty Pharma | 2.54B |
| Exelixis | 2.44B |
| Ascendis Pharma | 1.20B |
BNTX News
- 13 days ago - BioNTech to shutter sites in Germany, Singapore as no buyers emerge - Reuters
- 27 days ago - BioNTech says lung cancer drug candidate prolonged lives in trial - Reuters
- 27 days ago - BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients - GlobeNewsWire
- 6 weeks ago - BioNTech to terminate mid-stage trial of mRNA cancer vaccine - Reuters
- 6 weeks ago - US FDA approves updated COVID vaccines for 2026-27 season - Reuters
- 6 weeks ago - Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine - Business Wire
- 7 weeks ago - BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026 - GlobeNewsWire
- 2 months ago - BioNTech SE Earnings Call Transcript: Q2 2026 - Transcripts